Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Patient View

- PMLiVE

Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment

The rare neurodegenerative disorder has no cure and no approved treatments

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Impetus Digital

- PMLiVE

OPEN Health CSR Report 2019

Margot Hannah, Partner and Group Managing Director, and CSR lead at OPEN Health shares her thoughts on our latest report.

OPEN Health

- PMLiVE

Lundbeck drops Parkinson’s drug acquired in €905m deal

Disappointment after drug failed in a mid-stage clinical trial

- PMLiVE

Policy and public health: all the decisions we can’t see

January was a bad month for healthcare in China

- PMLiVE

Lundbeck gets US approval for migraine drug at heart of Alder takeover

US regulator clears CGRP inhibitor under Vyepti trade name

- PMLiVE

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Continues to bulk up its pipeline

- PMLiVE

Lundbeck’s key products shine in Q2 but problems remain

Faces increasing patent losses

- PMLiVE

Lundbeck snaps up Abide Therapeutics for $400m

Also acquires its lead drug for Tourette’s syndrome

- PMLiVE

GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing

Company seeking to revive lacklustre marketing performance

- PMLiVE

Transparency and accountability: tackling opacity and blame head-on

Let’s be honest, big pharma lacks trust and many love to hate it. Faceless corporations tainted by past own-goals, profiteering, cherry-picked data and spun claims - so goes the lazy...

- PMLiVE

Is trust in healthcare improving?

Edelman’s Annual Trust Barometer for 2017 painted a sobering picture of trust around the globe with a collapse in trust in all four of the major institutions studied - business,...

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links